UVAX-1197
/ Uvax Bio
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 05, 2025
A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV
(clinicaltrials.gov)
- P1 | N=25 | Suspended | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting ➔ Suspended
Trial suspension • Human Immunodeficiency Virus • Infectious Disease
August 18, 2025
A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV
(clinicaltrials.gov)
- P1 | N=25 | Recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Not yet recruiting ➔ Recruiting
Enrollment open • Human Immunodeficiency Virus • Infectious Disease
May 23, 2025
Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
(clinicaltrials.gov)
- P1 | N=34 | Completed | Sponsor: Uvax Bio LLC | Active, not recruiting ➔ Completed
Trial completion • Human Immunodeficiency Virus • Infectious Disease
April 01, 2025
A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV
(clinicaltrials.gov)
- P1 | N=25 | Not yet recruiting | Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
New P1 trial • Human Immunodeficiency Virus • Infectious Disease
August 07, 2024
Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.
(clinicaltrials.gov)
- P1 | N=34 | Active, not recruiting | Sponsor: Uvax Bio LLC
New P1 trial • Human Immunodeficiency Virus • Infectious Disease
1 to 5
Of
5
Go to page
1